scispace - formally typeset
A

Athol Wells

Researcher at Harefield Hospital

Publications -  15
Citations -  694

Athol Wells is an academic researcher from Harefield Hospital. The author has contributed to research in topics: Interstitial lung disease & Pulmonary function testing. The author has an hindex of 6, co-authored 15 publications receiving 638 citations.

Papers
More filters
Journal ArticleDOI

Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

TL;DR: In patients with moderate to severe bronchiectasis, mortality is associated with a degree of restrictive and obstructive disease, poor gas transfer and chronic pseudomonas infection, which should guide future research into disease progression, and identify those patients needing intensive treatment.
Journal ArticleDOI

HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation

TL;DR: There is good agreement between thoracic radiologists for the HRCT diagnosis of DPLD encountered in regional teaching centres, however, cases diagnosed with low confidence, particularly where NSIP is considered as a differential diagnosis, may benefit from the expertise of a reference panel.
Journal ArticleDOI

A comparison of serial computed tomography and functional change in bronchiectasis.

TL;DR: Altering in mucous plugging on serial CT were associated with changes in the severity of bronchiectasis and bronchial wall thickness, and greater severity of all three morphological abnormalities at baseline CT were predictive of significant declines in forced expiratory volume.
Journal ArticleDOI

Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis.

TL;DR: CALIPER-derived variables are the strongest CT predictors of mortality in HP, and automated CT stratification is equivalent to functional indices in the ILD-GAP model for predicting outcome in HP.
Journal Article

Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia

TL;DR: In the empirical treatment of advanced, rapidly progressive known or suspected NSIP, i.v. cyclophosphamide is a well tolerated, rapidly acting immunosuppressant, associated with improvement or stability in most cases.